MARKET

BDSX

BDSX

BIODESIX INC
NASDAQ
1.720
+0.060
+3.61%
After Hours: 1.730 +0.01 +0.58% 17:45 07/26 EDT
OPEN
1.730
PREV CLOSE
1.660
HIGH
1.730
LOW
1.675
VOLUME
58.94K
TURNOVER
0
52 WEEK HIGH
2.210
52 WEEK LOW
1.030
MARKET CAP
197.26M
P/E (TTM)
-3.1473
1D
5D
1M
3M
1Y
5Y
1D
Biodesix Price Target Announced at $3.00/Share by Craig-Hallum
Dow Jones · 9h ago
Biodesix Initiated at Buy by Craig-Hallum
Dow Jones · 9h ago
Craig-Hallum Initiates Coverage On Biodesix with Buy Rating, Announces Price Target of $3
Benzinga · 9h ago
BIODESIX, INC. <BDSX.O> : CRAIG-HALLUM INITIATES COVERAGE WITH BUY RATING AND TARGET PRICE $3
Reuters · 14h ago
U.S. RESEARCH ROUNDUP-Alexander & Baldwin, Instructure Holdings, RPM International
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Alexander & Baldwin, Instructure Holdings, RPM International and UnitedHealth Group among companies. American Airlines, Apple and Abbvie among companies with revised targets. The analysts also raised their ratings on several other companies.
Reuters · 18h ago
Press Release: Biodesix to Report Second Quarter 2024 Financial Results on August 7, 2024
Dow Jones · 2d ago
Biodesix to Report Second Quarter 2024 Financial Results on August 7, 2024
Biodesix, Inc. Will release financial results for the second quarter ended June 30, 2024 after the close of trading on August 7. The company will host a conference call and webcast to discuss its financial results and provide a business update. BiodesIX is a leading diagnostic solutions company with five Medicare-covered lung diseases tests.
Barchart · 2d ago
Medpace (MEDP) Tops Q2 Earnings Estimates
NASDAQ · 4d ago
More
About BDSX
Biodesix, Inc. (Biodesix) is a diagnostic solutions and services company. The Company develops diagnostic tests addressing clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix offers over five Medicare-covered tests for patients with lung diseases. The blood based Nodify Lung Nodule Risk Assessment testing strategy, consisting of the Nodify XL2 and the Nodify CDT tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the appropriate course of action. The blood based IQLung strategy for lung cancer patients integrates the GeneStrat targeted ddPCR test, the GeneStrat NGS test and the VeriStrat test to support treatment decisions across all stages of lung cancer. Biodesix also leverages the advanced Diagnostic Cortex artificial intelligence (AI) platform, to collaborate with biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease.

Webull offers Biodesix Inc stock information, including NASDAQ: BDSX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BDSX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BDSX stock methods without spending real money on the virtual paper trading platform.